03681 SINOMAB BIO-B
- 1.650
- +0.050+3.13%
SINOMAB BIO-B News
Sinomab Bioscience Administers First Dose of Atopic Dermatitis Drug
Sinomab Bioscience (HKG:3681) said the first patient received a dose of SM17 during a Phase I clinical trial of the company's treatment for Atopic Dermatitis, according to a Tuesday filing on the Hong
SinoMab Doses First Patient in Clinical Study of Atopic Dermatitis Drug in China
SinoMab BioScience (HKG:3681) successfully dosed the first patient in its phase 1b clinical trial of SM17 for treating atopic dermatitis in China, a Tuesday filing on the Hong Kong bourse said. Price
China Antibody-B (03681): The first patient in the Phase 1b clinical trial in China was treated with SM17.
China Antibody-B (03681) issued a notice on June 5, 2024, regarding the treatment of atopic dermatitis with SM17...
SINOMAB BIO-B: Annual Report 2023
China Antibody-B (03681) released annual results, achieving revenue of 1.3665 million yuan, and all businesses achieved expected performance
China Antibody-B (03681) announced its annual results for the year ended December 31, 2023, and the group achieved revenue...
SINOMAB BIO-B: ANNUAL RESULTS ANNOUNCEMENTFOR THE YEAR ENDED 31 DECEMBER 2023;CHANGE IN USE OF PROCEEDS;PROPOSED AMENDMENT TO THE 2022 SHARE OPTION SCHEME; ANDPROPOSED REFRESHMENT OF SCHEME MANDATE LIMIT AND SERVICE PROVIDER SUBLIMIT
China Antibody-B (03681.HK) plans to hold a board meeting on March 25 to consider and approve annual results
Gelonghui March 12 | China Antibody-B (03681.HK) announced that a board meeting will be held on March 25, 2024 (Monday) to consider and approve the Group's annual results and announcements for the year ended December 31, 2023, and to deal with other matters.
SINOMAB BIO-B: DATE OF BOARD MEETING
China Antibody-B (03681): Wang Shanchun appointed as Executive Director
China Antibody-B (03681) announced that Wang Shanchun has been appointed as the company's executive director since February 2024...
China Antibody-B completed the issuance of a total of 8.512,600 subscribed shares
China Antibody-B (03681) announced that since the prerequisites contained in the remaining two subscription agreements have been met, the two subscription agreements were completed on January 31, 2024 in accordance with the terms and conditions of the relevant subscription agreements. A total of 8,512,600 shares, which is equivalent to approximately 0.79% of the company's issued share capital immediately before completing the remaining two subscription agreements; and approximately 0.78% of the company's issued share capital expanded by issuing subscription shares, which have been issued to subscribers at a subscription price of HK$1.29 per subscribed share. The net proceeds from the subscription process will be approximately HK$10.9813 million as per the announcement
SinoMab BioScience Raises HK$62.2 Million From Thirteen Share Subscriptions
SinoMab BioScience (HKG:3681) raised net proceeds worth HK$62.2 million from the completion of thirteen share subscriptions. An aggregate of 48,322,093 shares were issued to subscribers for HK$1.29 ap
China Antibody-B (03681) completed the issuance of 48.321 million subscribed shares
China Antibody-B (03681) issued an announcement. Since the prerequisites contained in the 13 subscription agreements have been met, according to...
Hong Kong Stock Concept Tracker | Important! A new drug for Alzheimer's disease has been approved in China, and the drug development and diagnosis industry chain is worth paying attention to (with concept stocks)
The Guojin Securities Research Report pointed out that there are many pharmaceutical companies participating in AD research and development in China, and there are pharmaceutical companies worthy of attention in terms of biopharmaceuticals and chemicals.
Chinese antibody-B [03681] is now reported at HK$1.52, a decrease of 12.64%
As of 15:48, China Antibody B [03681] reported HK$1.52, down HK$0.22 or 12.64% from last year's closing price, with a turnover of HK$11.27 million, today's highest price of HK$1.85, and the lowest price of HK$1.52. Based on yesterday's closing price, the 10-day average price is HK$1.50 and the 50-day average price is HK$1.21. The current price-earnings ratio is -5.42 times, and the 14-day strength index is reported at 86.49.
Chinese antibody-B [03681] is now reported at HK$1.74, an increase of 10.13%
As of 15:59, China Antibody B [03681] reported HK$1.74, up HK$0.16 or 10.13% from yesterday's closing price of HK$1.58, with a turnover of HK$424,900, today's highest price of HK$1.74, and the lowest price of HK$1.58. Based on yesterday's closing price, the 10-day average price is HK$1.45 and the 50-day average price is HK$1.19. The current price-earnings ratio is -4.92 times. The 14-day strength index is 82.76.
SinoMab BioScience Issues 56.8 Million Shares to 15 Investors
SinoMab BioScience (HKG:3681) issued 56,834,719 shares to 15 investors at HK$1.29 apiece for a total of HK$73.3 million, a Thursday filing said. The net subscription price is seen to be at HK$73.2 mil
China Antibody (03681) plans to discount 18.35% of shares and net raise approximately HK$73.1818 million
Jinwu Financial News | China Antibody (03681) announced that it has issued a total of 56.834,700 shares, accounting for about 5.21% of the expanded share capital. The placement price is HK$1.29 per share, a discount of about 18.35% from the closing price of HK$1.58 on the previous trading day. The total amount of proceeds from the placement was HK$73,316,800, representing a net amount of approximately HK$73.1818 million. The company plans to use 35% of the net proceeds for the marketing and commercialization of Susciralimab (Susciralimab), including the establishment of sales and marketing teams, post-marketing medical activities, and marketing and academic promotion activities; 20% for
SinoMab Doses First Batch of Subjects in Phase 1 Trial of Atopic Dermatitis Drug in China
SinoMab BioScience (HKG:3681) dosed the first batch of subjects in the Phase 1 trial of its SM17 drug in China, according to a Monday filing. The trial intends to determine the safety, pharmacokinetic
China Accepts Clinical Trial Application for SinoMab BioScience's Alzheimer's Treatment; Shares Rise 3%
China's medical products administrator accepted SinoMab BioScience's (HKG:3681) clinical trial application for its Suciraslimab drug for mild cognitive impairment or mild dementia due to Alzheimer's d
Selected Gelonghui Announcements (Hong Kong Stocks) | China Huarong (02799.HK) Plans to Transfer 5.01% of CITIC Shares for HK$13.63 billion
[Today's focus] China Huarong (02799.HK) plans to transfer 5.01% of CITIC's shares for HK$13.63 billion. China Huarong (02799.HK) announced that on November 15, 2023, the company signed a share transfer agreement with CITIC Group and CITIC Shengxing (a wholly-owned subsidiary of CITIC Group). According to this, CITIC Shengxing conditionally agreed to transfer and the company conditionally agreed to transfer the target shares, accounting for 5.01% of the number of shares issued by CITIC. The total cost of the acquisition was HK$13.63 billion. After the acquisition is completed, the company will hold 5.01% of the issued shares of CITIC shares
Analysis
Price Target
No Data
